Biotechnology

Decades of scientific progress in understanding the root cause of many formerly intractable diseases has opened up new treatment options, namely through RNA-based therapies. This second wave of biopharma, in which our understanding of the ways coding portions of our genome relate to disease, allows us to intercede earlier, and at more specific and effective junctures.

What are the environmental impacts of single-use technology and stainless steel systems? And which should you use in your next facility?

Could your facility be working harder for you? If you have (or anticipate having) small-scale cell therapies in your pipeline, this question is vital.

Increasingly, manufacturers want standard facility designs of their GMP manufacturing facilities so they can be replicated elsewhere in the world, but this approach comes with unique considerations.

Commercializing cell and gene therapies efficiently requires timely decisions about whether to engage a CDMO or develop internal manufacturing capacity. Sometimes the best solution is to do both.

Changing the way therapies work, and the changing work of making therapies.

To bring the exciting science of cell and gene therapy manufacturing to life, creating smaller-scale filling solutions is imperative to the success of the ATMP industry. But before you begin scaling your operation, there are important questions to consider about fill-finish in ATMP.